Remote exposure to xenon produces delayed preconditioning against myocardial infarction in vivo: Additional evidence that noble gases are not biologically inert

Anesthesia and Analgesia

Volumn 107, Issue 6, 2008, Pages 1768-1771

  Pagel, Paul S ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGON; CYCLOOXYGENASE 2; HELIUM; INHALATION ANESTHETIC AGENT; ISOFLURANE; NEON; SEVOFLURANE; XENON;

ANESTHESIA INDUCTION; CLINICAL TRIAL; DRUG COST; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ANIMAL; HEART INFARCTION PREVENTION; NOTE; PHYSIOLOGY; RAT;

ANIMALS; CYCLOOXYGENASE 2; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; RATS; XENON;

EID: 58149302634     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181887506     Document Type: Editorial

References (49)

1. Lawrence JH, Loomis WF, Tobias CA, Turpin FH. Preliminary observations on the narcotic effect of xenon with a review of values for solubilities of gases in water and oils. J Physiol (London) 1946;105:197-204
2. Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951;113:580-2
3. Kennedy RR, Stokes JW, Downing P. Anaesthesia and the 'inert' gases with special reference to xenon. Anaesth Intensive Care 1992;20:66-70
4. Lane GA, Nahrwold ML, Tait AR, Taylor-Busch M, Cohen PJ, Beaudoin AR. Anesthetics as teratogens: nitrous oxide is fetotoxic, xenon is not. Science 1980;210:899-901
5. Steward A, Allott PR, Cowles AL, Mapleson WW. Solubility coefficients for inhaled anaesthetics in water, oil and biological media. Br J Anaesth 1973;45:282-93
6. Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anesthesiology 1997;86:1273-8
7. Preckel B, Ebel D, Mullenheim J, Frassdorf J, Thamer V, Schlack W. The direct myocardial effects of xenon in the dog heart in vivo. Anesth Analg 2002;94:545-51
8. Yagi M, Mashimo T, Kawaguchi T, Yoshiya I. Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: comparison with nitrous oxide. Br J Anaesth 1995;74:670-3
9. Preckel B, Weber NC, Sanders RD, Maze M, Schlack W. Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology 2006;105:187-97
10. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, Vallet B, Giunta F, Del Turco M, Erdmann W, Tenbrinck R, Hammerle AF, Nagele P; Xenon Study Group. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 2003;98:6-13
11. Coburn M, Kunitz O, Baumert JH, Hecker K, Zuhlsdorff A, Beeker T, Rossaint R. Randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia. Br J Anaesth 2005;94:198-202
12. Baumert JH, Falter F, Eletr D, Hecker KE, Reyle-Hahn M, Rossaint R. Xenon anaesthesia may preserve cardiovascular function in patients with heart failure. Acta Anaesthesiol Scand 2005;49:743-9
13. Lockwood GG, Franks NP, Downie NA, Taylor KM, Maze M. Feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass. Anesthesiology 2006;104:458-65
14. Saito H, Saito M, Goto T, Morita S. Priming of anesthesia circuit with xenon for closed circuit anesthesia. Artif Organs 1997;21:70 -72
15. Preckel B, Mullenheim J, Moloschavij A, Thamer V, Schlack W. Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo. Anesth Analg 2000;91:1327-32
16. Weber NC, Toma O, Wolter JI, Obal D, Mullenheim J, Preckel B, Schlack W. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-e and p38 MAPK. Br J Pharmacol 2005;144:123-32
17. Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, Preckel B. Mechanisms of xenon- and isoflurane-induced preconditioning. A potential link to the cytoskeleton via the MAPKAPK- 2/HSP27 pathway. Br J Pharmacol 2005;146:445-55
18. Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B. Xenon preconditioning differently regulates p44/42 MAPK (ERK1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo.Br J Anaesth 2006;97:298-306
19. Weber NC, Toma O, Damla H, Wolter JI, Schlack W, Preckel B. Upstream signaling of PKC-e in xenon-induced pharmacological preconditioning. Implication of mitochondrial KATP channels and PDK-1. Eur J Pharmacol 2006;539:1-9
20. Mio Y, Shim YH, Richards E, Bosnjak ZJ, Pagel PS, Bienengraeber M. Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition, and bioenergetics in rats. Anesth Analg (in press)
21. Weber NC, Kandler J, Schlack W, Grueber Y, Frassdorf J, Preckel B. Intermitted pharmacolgic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor -induced adhesion molecule expression in human umbilical vein endothelial cells. Anesthesiology 2008;108:199-207
22. Koblin DD, Fang Z, Eger EI II, Laster MJ, Gong D, Ionescu P, Halsey MJ, Trudell JR. Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexafluoride in rats: helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg 1998;87:419-24
23. Trudell JR, Koblin DD, Eger EI II. A molecular description of how noble gases and nitrogen bind to a model site of anesthetic action. Anesth Analg 1998;87:411-8
24. Pagel PS, Krolikowski JG, Venkatapuram S, Shim YH, Kersten JR, Weihrauch D, Warltier DC, Pratt PF Jr. Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg 2007;105:562-9
25. Pagel PS, Krolikowski JG, Pratt PF Jr, Shim YH, Amour J, Warltier DC, Weihrauch D. Mechanism of helium-induced preconditioning: a direct role for nitric oxide in rabbits. Anesth Analg 2008;107:762-8
26. Pagel PS, Krolikowski JG, Weihrauch D, Shim YH, Amour J, Warltier DC, Pratt PF Jr. Inhibition of glycogen synthase kinase or the apoptotic protein p53 lowers the threshold of helium cardioprotection in vivo: the role of mitochondrial permeability transition. Anesth Analg 2008;107:769-75
27. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004;100:707-21
28. Weber NC, Frassdorf J, Ratajczak C, Grueber Y, Schlack W, Hollmann MW, Preckel B. Xenon induces late cardiac preconditioning in vivo. A role for COX-2? Anesth Analg 2008;107
29. Bolli R. The late phase of preconditioning. Circ Res 2000;87:972-83
30. Tanaka K, Ludwig LM, Krolikowski JG, Alcindor D, Pratt PF, Kersten JR, Pagel PS, Warltier DC. Isoflurane produced delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology 2004;100:525-31
31. Tonkovic-Capin M, Gross GJ, Bosnjak ZJ, Tweddell JS, Fitzpatrick CM, Baker JE. Delayed cardioprotection by isoflurane: role of KATP channels. Am J Physiol Heart Circ Physiol 2002;283:H61-8
32. Lutz M, Liu H. Inhaled sevoflurane produces better delayed myocardial protection at 48 versus 24 hours after exposure. Anesth Analg 2006;102:984-90
33. Mullenheim J, Ebel D, Bauer M, Otto F, Heinen A, Frassdorf J, Preckel B, Schlack W. Sevoflurane confers additional cardioprotection after ischemic late preconditioning in rabbits. Anesthesiology 2003;99:624-31
34. Kehl F, Pagel PS, Krolikowski JG, Gu W, Toller W, Warltier DC, Kersten JR. Isoflurane does not produce a second window of preconditioning against myocardial infarction in vivo. Anesth Analg 2002;95:1162-8
35. Lucchinetti E, Hofer C, Bestmann L, Hersberger M, Feng J, Zhu M, Furrer L, Schaub MC, Tavakoli R, Genoni M, Zollinger A, Zaugg M. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology 2007;106:444 -57
36. Chiari PC, Bienengraeber MW, Weihrauch D, Krolikowski JG, Kersten JR, Warltier DC, Pagel PS. Role of endothelial nitric oxide synthase as a trigger and mediator of isoflurane-induced delayed preconditioning in rabbit myocardium. Anesthesiology 2005;103:74-83
37. Wakeno-Takahashi M, Otani H, Nakao S, Imamura H, Shingu K. Isoflurane induces second window of preconditioning through upregulation of inducible nitric oxide synthase in rat heart. Am J Physiol Heart Circ Physiol 2005;289:H2585-91
38. Shi Y, Hutchins WC, Su J, Siker D, Hogg N, Pritchard KA, Keszler A, Tweddell JS, Baker JE. Delayed cardioprotection with isoflurane: role of reactive oxygen and nitrogen. Am J Physiol Heart Circ Physiol 2005;288:H175-84
39. Tsutsumi YM, Patel HH, Huang D, Roth DM. Role of 12-lipoxygenase in volatile anesthetic-induced delayed preconditioning in mice. Am J Physiol Heart Circ Physiol 2006;291:H979 - 83
40. Coburn M, Maze M, Franks NP. The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008;36:588-95
41. Xu Y, Tang P. Amphiphilic sites for general anesthesia action? Evidence from 129Xe-{1H} intermolecular nuclear Overhauser effects. Biochim Biophys Acta 1997;1323:154-62
42. Schlitz M, Fourme R, Broutin I, Prange T. The catalytic site of serine proteinases as a specific binding cavity for xenon. Structure 1995;3:309-16
43. Prange T, Schlitz M, Pernot L, Colloch N, Longhi S, Bourguet W, Fourme R. Exploring hydrophobic sites in proteins with xenon or krypton. Proteins 1998;30:61-73
44. LaBella FS, Stein DGQ. The site of general anesthesia and cytochrome P450 monooxygenases: occupation of the enzyme heme pocket by xenon and nitrous oxide. Eur J Pharmacol 1999;381:R1-3
45. Dickinson R, Peterson BK, Banks P, Simillis C, Martin JCS, Velenzuela CA, Maze M, Franks NP. Competitive inhibition at the glycine site of the N-methyl-d-aspartate receptor by the anesthetics xenon and isoflurane. Evidence from molecular modeling and electrophysiology. Anesthesiology 2007;107: 756-67
46. Quillin ML, Breyer WA, Griswold IJ, Matthews BW. Size versus polarizability in protein-ligand interactions: binding of noble gases within engineered cavities in phage T4 lyzozyme. J Mol Biol 2000;302:955-77
47. Mann G, Hermans J. Modeling protein-small molecule interactions: structure and thermodynamics of noble gases binding in a cavity in mutant phage T4 lysozyme L99A. J Mol Biol 2000;302:979-89
48. Milano G, Morel S, Bonny C, Samaja M, von Segesser LK, Nicod P, Vassalli G. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol 2007;292:H1828-35
49. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007;116:173-91